WO2019160023A1 - Composition pour prévention d'apoplexie - Google Patents

Composition pour prévention d'apoplexie Download PDF

Info

Publication number
WO2019160023A1
WO2019160023A1 PCT/JP2019/005300 JP2019005300W WO2019160023A1 WO 2019160023 A1 WO2019160023 A1 WO 2019160023A1 JP 2019005300 W JP2019005300 W JP 2019005300W WO 2019160023 A1 WO2019160023 A1 WO 2019160023A1
Authority
WO
WIPO (PCT)
Prior art keywords
casein hydrolyzate
present technology
indigestible dextrin
mass
stroke
Prior art date
Application number
PCT/JP2019/005300
Other languages
English (en)
Japanese (ja)
Inventor
明日翔 多田
美順 田中
越智　大介
Original Assignee
森永乳業株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 森永乳業株式会社 filed Critical 森永乳業株式会社
Publication of WO2019160023A1 publication Critical patent/WO2019160023A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

L'invention fournit une composition pour prévention d'apoplexie qui présente peu d'effets secondaires et se révèle d'un niveau de sécurité élevé. Plus précisément, l'invention concerne une composition pour prévention d'apoplexie qui contient un hydrolysat de caséine et une dextrine résistante à la digestion. De préférence, ledit hydrolysat de caséine contient un peptide constitué de Ｍｅｔ－Ｌｙｓ－Ｐｒｏ. En outre, de préférence, ledit hydrolysat de caséine contient un peptide constitué de Ｍｅｔ－Ｌｙｓ－Ｐｒｏ, et la teneur en dextrine résistante à la digestion est comprise entre 5000 et 10000 parties en masse pour 1 partie en masse de peptide.
PCT/JP2019/005300 2018-02-16 2019-02-14 Composition pour prévention d'apoplexie WO2019160023A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018-026407 2018-02-16
JP2018026407 2018-02-16

Publications (1)

Publication Number Publication Date
WO2019160023A1 true WO2019160023A1 (fr) 2019-08-22

Family

ID=67619443

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2019/005300 WO2019160023A1 (fr) 2018-02-16 2019-02-14 Composition pour prévention d'apoplexie

Country Status (1)

Country Link
WO (1) WO2019160023A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7344722B2 (ja) 2019-09-04 2023-09-14 森永乳業株式会社 構成行為改善用組成物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3090950B2 (ja) * 1994-04-19 2000-09-25 鐘紡株式会社 循環器系疾患予防剤
JP2017031105A (ja) * 2015-08-03 2017-02-09 森永乳業株式会社 食後血糖値の上昇抑制を促進させる剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3090950B2 (ja) * 1994-04-19 2000-09-25 鐘紡株式会社 循環器系疾患予防剤
JP2017031105A (ja) * 2015-08-03 2017-02-09 森永乳業株式会社 食後血糖値の上昇抑制を促進させる剤

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
OTANI L ET AL.: "Sardine peptide with angiotensin I converting enzyme inhibitory activity improves glucose tolerance in stroke-prone spontaneously hypertensive rats", BIOSCI BIOTECHNOL BIOCHEM., vol. 73, no. 10, 2009, pages 2203 - 2209, XP055635011 *
SHINDO, AKIHIRO ET AL: "Neurology of diabetes Revisited, Diabetes and cerebral infarction", BRAIN AND NERVE, vol. 66, no. 2, 2014, pages 107 - 119 *
UEHARA YOSHIO ET AL: "Animal model of kidney disease, high blood pressure model, spontaneously hypertensive rats (SHR)", NEPHROLOGY FRONTIER, vol. 08, no. 03, 2009, pages 291 - 293, ISSN: 1346-9630 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7344722B2 (ja) 2019-09-04 2023-09-14 森永乳業株式会社 構成行為改善用組成物

Similar Documents

Publication Publication Date Title
JP6344796B2 (ja) 高齢者用アルツハイマー型認知症改善剤
US11324784B2 (en) Sleep-promoting composition, and medical composition and food beverage composition using said sleep-promoting composition
JP2017031105A (ja) 食後血糖値の上昇抑制を促進させる剤
JP7358239B2 (ja) エネルギー消費促進用組成物
JP7062460B2 (ja) 発酵乳の製造方法
WO2019160023A1 (fr) Composition pour prévention d'apoplexie
WO2019188943A1 (fr) Composition pour prévenir et/ou améliorer une diminution du débit sanguin cérébral
WO2019160024A1 (fr) Composition pour hypotension artérielle et/ou réduction des graisses neutres
WO2022202985A1 (fr) Peptide et composition contenant ce peptide en tant que principe actif
WO2021059894A1 (fr) Composition, composition d'aliment/boisson qui contient ladite composition, et lait modifié
JP2021164423A (ja) ラクノスピラ科細菌増殖用組成物
CN111936155B (zh) 促进fgf21分泌用组合物
JP2021126067A (ja) Ｎａｍｐｔ発現促進組成物
JP6778094B2 (ja) カゼイン酵素分解物の製造方法及びカゼイン酵素分解物
JP2019142791A (ja) 血圧降下用及び／又は中性脂肪低減用の組成物
JP2016121109A (ja) 表皮基底膜保護剤
JP2020132621A (ja) 皮膚ガス放散調節用組成物
JP6964635B2 (ja) 見当識改善用組成物
JP7344722B2 (ja) 構成行為改善用組成物
WO2024038888A1 (fr) Composition
JP6589011B2 (ja) 脳機能障害改善用経口組成物
JP2015189672A (ja) 概日リズム改善剤
JP7309436B2 (ja) 腎機能障害予防又は改善用組成物、並びに、該腎機能障害予防又は改善用組成物を用いた医薬品組成物及び飲食品組成物
JP6309367B2 (ja) カゼイン加水分解物の製造方法
WO2024071404A1 (fr) Nouveau peptide et composition antioxydante

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19753604

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19753604

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP